Form 4: BeOne Medicines GC Sells Shares Via 10b5-1 Plan

BeOne Medicines' SVP and General Counsel, Chan Henry Lee, executed pre-planned sales of American Depositary Shares following option exercises.

Summary

• SVP, General Counsel Chan Henry Lee engaged in multiple transactions on August 13, 2025, under a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Exercised options to acquire 56,953 Ordinary Shares at an exercise price of $14.96 per share.
• Exercised options to acquire 50,037 Ordinary Shares at an exercise price of $12.23 per share.
• Acquired 4,381 American Depositary Shares (ADS) at $194.47 per ADS and 3,849 ADSs at $159.03 per ADS through option exercises (Note: 1 ADS represents 13 Ordinary Shares).
• Sold a total of 11,013 American Depositary Shares (ADS) in multiple transactions.
• Sales included 1,112 ADSs at $300.00, 6,052 ADSs at a weighted average price of $300.1858 (ranging from $300.00 to $300.98), and 3,849 ADSs at a weighted average price of $301.001 (ranging from $301.00 to $301.03).
• Following these transactions, the reporting person directly owns 252,018 Ordinary Shares and 0 American Depositary Shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be a negative signal, the fact that it's part of a pre-planned 10b5-1 program mitigates concerns about opportunistic selling based on negative undisclosed information. It represents an executive monetizing vested equity at favorable prices.

Positives

• Transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new negative information.
• The sales occurred at high prices (around $300 per ADS), indicating the insider capitalized on favorable market conditions.
• The exercise prices for the options ($14.96 and $12.23 per Ordinary Share) are significantly lower than the ADS sale prices, demonstrating substantial personal profit for the insider.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

This filing reflects a routine insider transaction for an executive at a pharmaceutical or biotechnology company (given 'Medicines' in the name and 'ONC' ticker, possibly oncology-focused). Such transactions are common for executives managing their personal portfolios, especially when options vest and become exercisable. The use of a 10b5-1 plan is standard practice to avoid accusations of trading on material non-public information.

Related Party Transactions

• The transactions involve an executive (SVP, General Counsel) of BeOne Medicines Ltd. selling company shares, which is a standard related-party transaction reported on Form 4.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The sale at high prices indicates the executive believes the current price is attractive for monetization.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details routine insider transactions by an executive under a pre-arranged 10b5-1 plan. While it involves selling shares, this is a common practice for executives to manage their personal finances and diversify their holdings, especially after exercising options. It does not signal new negative information about the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment thesis based solely on this filing.

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Trading, Stock Sale, Option Exercise, 10b5-1 Plan, American Depositary Shares, Corporate Governance, Executive Compensation